Anti–Alpha-Synuclein Immunotherapy

Great to hear. Kind of related? I was just reading about genipin a supplement possibly that helps clear a-synuclein.

That’s an interesting and unique story. My case is similarly odd - I landed at the neurologist with autonomic issues, dysphagia, dyspnea, fasciculations, and balance issues. I had a datscan ordered basically as a method of exclusion, doctor and I were equally surprised at the results. That’s what spurred the biopsy which also came back positive for alphasynuclein.

My symptoms are much more in line with MSA, yet I don’t fit the clinical picture for MSA because I’ve been ill for 4 years and should be in much worse shape after so much time if that was the case. I don’t have a tremor, bradykinesia, or stiffness. Nobody can tell I’m ill and I’m still at work doing a very physical job. Even with positive results on both tests, my clinical picture is too obscure to say anything.

DatScan can’t diagnose Parkinson’s, it just images neurodegeneration in the basal ganglia and striatum negra. A positive DatScan can also indicate MSA, PSP, CBD, DLB.

Similarly, the skin biopsy can’t diagnose Parkinson’s, it can only detect alphasynuclein.

Both of these tests are indicative of Parkinsonisms, but there’s more diseases besides PD that will show results on these tests.

The biopsy is still very new like you said, relatively speaking. There’s reports that it potentially has specificity (being able to distinguish which disease by the “signature” of how the alphasynuclein is distributed throughout the biopsy sites), but at the moment there aren’t enough numbers to back it up on a clinical level.

Anti–Alpha-Synuclein Immunotherapy is a promising new approach to treating Parkinson's disease. It targets alpha-synuclein, a protein that builds up in the brains of people with Parkinson's, causing damage. There are two main strategies: one uses lab-engineered antibodies to help the immune system break down harmful forms of alpha-synuclein, while the other involves a vaccine that trains the body to attack the protein. Early studies have shown progress, with some treatments advancing to Phase 3 trials, which test their effectiveness. This represents a significant shift from older, less targeted treatments and offers hope for slowing the disease's progression.

Anti-alpha-synuclein immunotherapy is a promising approach for treating Parkinson's disease. Experts explain that Parkinson's is linked to the accumulation of alpha-synuclein, a sticky protein that forms toxic clumps in the brain. This therapy uses antibodies or T-cells to target and clear these clumps, potentially preventing their spread between neurons. Similar strategies have shown success in Alzheimer's disease, where antibodies helped clear harmful proteins. While still in early stages for Parkinson's, this method represents a shift towards addressing the disease's root causes rather than just its symptoms.

This paper reviewed recent clinical trials that focus on immune-based therapies targeting alpha-synuclein, a protein linked to Parkinson's disease progression. It analyzed both active immunization approaches, which stimulate the body's immune system to attack alpha-synuclein, and passive immunization approaches, which use lab-made antibodies to target the protein.

The review highlighted several therapies, including vaccines like UB-312 and monoclonal antibodies like Prasinezumab, showing some promise in targeting alpha-synuclein. However, it also noted challenges such as inconsistent results across trials and the discontinuation of some studies due to limited efficacy.

For people with Parkinson's or their caregivers, this paper underscores the potential of alpha-synuclein immunotherapy to slow disease progression, though it also highlights the need for further research to overcome current limitations. It provides hope for future treatments but emphasizes that these therapies are still in development.

As a systematic review published in the reputable Journal of Neurology, this paper is a reliable source. It synthesizes data from multiple clinical trials, offering a broad perspective on the current state of alpha-synuclein immunotherapy research.

This paper examined the safety and effectiveness of α-synuclein immunotherapy for treating Parkinson's disease. Researchers analyzed data from six randomized controlled trials involving 606 patients receiving the immunotherapy and 254 patients receiving a placebo.

The study found no significant difference in overall Parkinson's disease symptom scores, adverse events, headache, or constipation between the immunotherapy and placebo groups. However, the immunotherapy group had a higher infection rate compared to the placebo group.

For individuals with Parkinson's disease or their caregivers, this study suggests that α-synuclein immunotherapy may not provide significant benefits in managing symptoms and could increase the risk of infections. It highlights the need for further research before considering this treatment option.

This paper is a systematic review, which is considered a high-quality study type. It was published in a reputable journal, but the findings are limited by the small number of included trials and the need for larger, multi-center studies to confirm the results.